title: [Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase].
abstract: The efficacy and safety of sulbactam/cefoperazone (SBT/CPZ) were evaluated in 42 patients with respiratory tract infections, including pneumonia (29 patients) and lower respiratory tract infections (5 patients). Overall clinical efficacy rates (excellent + good) were 79% in pneumonia and 80% in respiratory tract infections in 34 patients evaluated for clinical efficacy. It was excellent that the clinical efficacy rate was 92% in mild and moderate pneumonia. Pathogens isolated from sputa were 31 strains, including 8 strains of Pseudomonas aeruginosa, 7 of Streptococcus pneumoniae, 3 of Staphylococcus aureus and 3 of Haemophilus influenzae. Since the isolates were eradicated in 18 strains, replaced in 3, unchanged in 2 and unknown in 8, the overall eradication rate was 91%. The eradication rates were 89% in beta-lactamase producing strains and 100% in beta-lactamase positive sputum, and excellent or good in 19 (83%) of 23 patients with beta-lactamase negative sputum. The eradication rate was 88% in 5 patients with beta-lactamase positive sputum. One patient experienced a moderate rash. Abnormal laboratory test values were observed in 10 patients (26.3%), but these abnormalities were mild and transient. These results suggested that SBT/CPZ was effective and safe for the treatment of respiratory tract infections caused by beta-lactamase producing as well as beta-lactamase non-producing bacteria.
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Koga
authors.forename: K
authors.initials: K
authors.lastname: Tomono
authors.forename: Y
authors.initials: Y
authors.lastname: Hirakata
authors.forename: S
authors.initials: S
authors.lastname: Kohno
authors.forename: K
authors.initials: K
authors.lastname: Abe
authors.forename: S
authors.initials: S
authors.lastname: Kawamoto
authors.forename: S
authors.initials: S
authors.lastname: Kusano
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: N
authors.initials: N
authors.lastname: Morikawa
authors.forename: H
authors.initials: H
authors.lastname: Sugiyama
authors.forename: T
authors.initials: T
authors.lastname: Katsumata
authors.forename: K
authors.initials: K
authors.lastname: Sasayama
authors.forename: K
authors.initials: K
authors.lastname: Shimoguchi
authors.forename: A
authors.initials: A
authors.lastname: Hashimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Ishiguro
authors.forename: H
authors.initials: H
authors.lastname: Hori
authors.forename: H
authors.initials: H
authors.lastname: Mashimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Dotsu
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Imamura
authors.forename: T
authors.initials: T
authors.lastname: Kanda
authors.forename: K
authors.initials: K
authors.lastname: Hara
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001419:Bacteria / Q000201:enzymology / Q000302:isolation & purification; D002438:Cefoperazone / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D013407:Sulbactam / Q000627:therapeutic use; D001618:beta-Lactamases / Q000096:biosynthesis
chemical_list: D000900:Anti-Bacterial Agents; D002438:Cefoperazone; D001618:beta-Lactamases; D013407:Sulbactam